Brokerages expect Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to announce earnings per share (EPS) of ($0.55) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Collegium Pharmaceutical’s earnings. The lowest EPS estimate is ($0.67) and the highest is ($0.34). Collegium Pharmaceutical posted earnings of ($1.02) per share in the same quarter last year, which suggests a positive year over year growth rate of 46.1%. The business is expected to issue its next quarterly earnings report on Thursday, March 8th.

According to Zacks, analysts expect that Collegium Pharmaceutical will report full-year earnings of ($2.56) per share for the current year, with EPS estimates ranging from ($2.89) to ($2.30). For the next fiscal year, analysts forecast that the firm will post earnings of ($1.45) per share, with EPS estimates ranging from ($1.82) to ($0.99). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.28. The company had revenue of $11.95 million during the quarter, compared to analysts’ expectations of $5.31 million. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The firm’s quarterly revenue was up 2814.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.13) earnings per share.

A number of equities analysts have issued reports on the stock. Piper Jaffray Companies restated a “buy” rating and set a $14.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, September 8th. BidaskClub cut shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of Collegium Pharmaceutical in a report on Friday, November 17th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $15.00 price target on shares of Collegium Pharmaceutical in a report on Friday, October 6th. Two investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. Collegium Pharmaceutical currently has an average rating of “Buy” and a consensus price target of $19.33.

Collegium Pharmaceutical (NASDAQ:COLL) opened at $16.30 on Friday. Collegium Pharmaceutical has a 52-week low of $7.37 and a 52-week high of $19.21.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/zacks-brokerages-expect-collegium-pharmaceutical-inc-coll-will-announce-earnings-of-0-55-per-share/1722721.html.

In other news, CTO Alison B. Fleming sold 4,029 shares of Collegium Pharmaceutical stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $17.00, for a total transaction of $68,493.00. Following the completion of the sale, the chief technology officer now directly owns 28,513 shares in the company, valued at $484,721. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Alison B. Fleming sold 4,601 shares of Collegium Pharmaceutical stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $17.25, for a total transaction of $79,367.25. Following the sale, the insider now owns 28,513 shares of the company’s stock, valued at $491,849.25. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 58,630 shares of company stock valued at $924,360. Insiders own 25.76% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in Collegium Pharmaceutical by 7.8% in the first quarter. Vanguard Group Inc. now owns 806,539 shares of the specialty pharmaceutical company’s stock valued at $8,113,000 after purchasing an additional 58,398 shares during the period. Teton Advisors Inc. purchased a new stake in Collegium Pharmaceutical in the third quarter valued at approximately $283,000. Bank of New York Mellon Corp grew its holdings in Collegium Pharmaceutical by 60.7% in the second quarter. Bank of New York Mellon Corp now owns 104,961 shares of the specialty pharmaceutical company’s stock valued at $1,313,000 after purchasing an additional 39,656 shares during the period. Teachers Advisors LLC grew its holdings in Collegium Pharmaceutical by 98.8% in the second quarter. Teachers Advisors LLC now owns 59,590 shares of the specialty pharmaceutical company’s stock valued at $745,000 after purchasing an additional 29,617 shares during the period. Finally, Pier Capital LLC grew its holdings in Collegium Pharmaceutical by 8.1% in the second quarter. Pier Capital LLC now owns 395,658 shares of the specialty pharmaceutical company’s stock valued at $4,950,000 after purchasing an additional 29,594 shares during the period. Institutional investors and hedge funds own 77.23% of the company’s stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.